Welcome to our dedicated page for Outset Medical news (Ticker: OM), a resource for investors and traders seeking the latest updates and insights on Outset Medical stock.
Outset Medical, Inc. develops and commercializes dialysis technology centered on the Tablo Hemodialysis System, an FDA-cleared platform used across hospital and home care settings. Company news commonly covers Tablo adoption, consumables and service revenue, product gross margin, cash use, and financial guidance tied to the company’s medical technology business.
Recurring updates also include FDA matters for the Tablo platform, including 510(k) clearance for a next-generation system with cybersecurity, reliability, and connectivity enhancements. Governance and compensation announcements include board changes, executive appointments, and inducement equity grants under Nasdaq rules.
Outset Medical (Nasdaq: OM) approved equity awards under its Inducement Plan for two newly hired non-executive employees, consistent with Nasdaq Listing Rule 5635(c)(4).
The awards total 45,000 restricted stock units (RSUs), vesting over three years with 33.33% after one year and the remaining 66.67% in quarterly installments, subject to continued service and possible acceleration or forfeiture.
Outset Medical (Nasdaq: OM) announced that its management will present at the RBC Capital Markets Global Healthcare Conference on Tuesday, May 19, 2026, at 10:30 a.m. ET.
A live and archived webcast will be accessible via the Investors section of the Outset Medical website.
Outset Medical (Nasdaq: OM) reported Q1 2026 results: revenue of $27.9M (-6% YoY) and recurring revenue of $22.5M roughly flat year-over-year. Gross margin expanded to 43.4% with record product and service margins. Net loss narrowed to $19.0M; cash totaled $161M. The company reiterated 2026 revenue guidance of $125M–$130M and non-GAAP gross margin in the low‑to‑mid 40% range.
Outset Medical (Nasdaq: OM) will report first quarter 2026 financial results after market close on Thursday, May 7, 2026. A conference call with CEO Leslie Trigg and CFO Renee Gaeta is scheduled the same day at 1:30 p.m. PT / 4:30 p.m. ET.
Registration is required to join the call; a live and archived webcast will be available on the company’s Investors website.
Outset Medical (Nasdaq: OM) reported inducement equity awards approved by its Compensation Committee under Nasdaq Listing Rule 5635(c)(4) for two new hires. The Company granted 96,000 RSUs to Derick Elliott, EVP of Commercial, and 10,380 RSUs to another new non-executive employee.
The RSUs vest over three years: 33.33% at the one-year anniversary and the remaining 66.67% in quarterly installments thereafter, subject to continued service and usual acceleration or forfeiture terms.
Outset Medical (Nasdaq: OM) appointed Derick Elliott as Executive Vice President of Commercial, effective April 6, 2026. Elliott will lead commercial teams across acute, post-acute and home care and report to Chair and CEO Leslie Trigg. He brings 30+ years of sales and marketing experience from Stryker, Cardinal Health and SpendMend.
The company noted Elliott’s experience with capital equipment, software, EMR connectivity and recurring revenue and cited nearly 1,000 acute facilities using Tablo.
Outset Medical (Nasdaq: OM) reported fourth-quarter and full-year 2025 results. Revenue was $28.9M in Q4 and $119.5M for 2025, up 5% year-over-year. Recurring revenue grew 6% to $88.7M. Gross margin expanded ~500–600 bps to 42.4% in Q4 and 39.1% for 2025. Year-end cash totaled $173M. The company received FDA clearance for its next-generation Tablo platform, expected to launch in Q2 2026. 2026 revenue guidance is $125M–$130M with non-GAAP gross margin in the low- to mid-40% range.
Outset Medical (Nasdaq: OM) announced FDA 510(k) clearance for its next-generation Tablo hemodialysis platform on Jan 27, 2026. The platform is the first dialysis system cleared to meet the FDA's June 2025 guidance on medical device cybersecurity and includes hardware, operating system, and software enhancements to improve reliability, performance, and durability. The next-generation Tablo is expected to begin shipping to customers in Q2 2026, and existing Tablo users will be eligible for an upgrade to the new cybersecurity platform.
Outset Medical (Nasdaq: OM) will report fourth quarter and full-year 2025 financial results after market close on Wednesday, February 11, 2026. A conference call with Leslie Trigg, Chair and CEO, and Renee Gaeta, CFO, will be held the same day at 1:30 p.m. PT / 4:30 p.m. ET to discuss financial and operating results. Interested participants must register online to receive dial-in numbers and a unique PIN, and are encouraged to register at least 15 minutes before the call. A live and archived webcast will be available in the Investors section of the company's website.
Outset Medical (Nasdaq: OM) reported unaudited revenue of $28.9M for Q4 and $119.5M for full-year 2025, a 5% increase versus $113.7M in 2024. The company said more than 1,000 care sites have insourced dialysis on Tablo, performing roughly 1M treatments per year and >3M cumulative treatments. Year-end cash and short-term investments totaled $173M. Net cash used in operations for 2025 was reported as below $50M versus $116M in 2024. Outset announced a board appointment: Karen N. Prange joins the board and Compensation Committee, replacing Andrea Saia. Management cited a strong backlog and growing pipeline entering 2026.